there's sma foundation based here in new york and a consortium in europe, sma europe, all pretty much with the same idea of trying to provide individual educational sport to parents so they can make the right choices. it brings up a difficult challenge which is when is the treatment most likely to be effective. probably early on in the course before they have had this loss of the motor neurons because we don't yet know how to replace those. so the idea is if we have all these babies because half of sma are the little type 1 babies, are we going to have to start doing newborn screening to pick them up before they show signs of sma. that gets into a real thorny ethical dilemma and also a lot of technical challenges there. but that's really what the field is exploring at the moment. >> pick up on this conversation here about understanding the causes. >> . >> als is very different from sma in its causes. it is predominantly a spor atic disease that is, typically occurs in patients with no family history as is the case. >> correct. >> but in about 10% of cases of als it's familiarial that